galantamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1272 357-70-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • galantamine
  • galantamin
  • galantamina
  • lycoremin
  • lycoremine
  • galanthamine
  • (-)-Galantamine
  • (-)-Galanthamine
  • galantamine hydrobromide
  • galanthamine hydrobromide
A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.
  • Molecular weight: 287.36
  • Formula: C17H21NO3
  • CLOGP: 1.02
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 41.93
  • ALOGS: -2.23
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
16 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.45 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.83 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 28, 2001 FDA JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Orthostatic hypotension 1340.60 42.78 390 7999 35770 63444863
Sedation complication 1330.66 42.78 318 8071 13504 63467129
Creatinine renal clearance decreased 1323.80 42.78 327 8062 15981 63464652
Sedation 1252.33 42.78 376 8013 38433 63442200
Cognitive disorder 1193.89 42.78 395 7994 55420 63425213
Blood calcium decreased 1157.79 42.78 325 8064 26126 63454507
Balance disorder 1019.62 42.78 391 7998 84031 63396602
Depressed level of consciousness 937.43 42.78 339 8050 61739 63418894
Mobility decreased 672.20 42.78 324 8065 120835 63359798
Constipation 662.05 42.78 394 7995 224549 63256084
Fall 651.32 42.78 480 7909 391854 63088779
Hypotension 611.93 42.78 402 7987 272202 63208431
Toxicity to various agents 492.46 42.78 339 8050 246911 63233722
Pain 159.99 42.78 320 8069 740308 62740325
Drug ineffective 100.19 42.78 11 8378 1044754 62435879
Multiple drug therapy 90.36 42.78 29 8360 3617 63477016
Fatigue 70.08 42.78 16 8373 888012 62592621
Product dispensing error 52.08 42.78 26 8363 10279 63470354
Pleurothotonus 51.68 42.78 15 8374 1334 63479299
Marasmus 44.81 42.78 11 8378 514 63480119
Rash 44.33 42.78 10 8379 560861 62919772

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 63.39 25.03 84 3051 202801 34750995
Dysphagia 36.77 25.03 36 3099 62345 34891451
Aggression 35.97 25.03 29 3106 38935 34914861
Post-traumatic stress disorder 35.14 25.03 11 3124 1870 34951926
Compartment syndrome 33.79 25.03 12 3123 3006 34950790
Fracture 33.58 25.03 15 3120 6834 34946962
Agitation 31.73 25.03 32 3103 57367 34896429
Hallucination 30.86 25.03 30 3105 51468 34902328
Increased bronchial secretion 26.97 25.03 9 3126 1872 34951924
Loss of consciousness 25.31 25.03 34 3101 82633 34871163

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 1367.90 32.72 334 10307 15335 79718412
Creatinine renal clearance decreased 1318.66 32.72 337 10304 18665 79715082
Orthostatic hypotension 1193.72 32.72 397 10244 55767 79677980
Sedation 1171.66 32.72 384 10257 51511 79682236
Cognitive disorder 1150.30 32.72 408 10233 69518 79664229
Blood calcium decreased 1137.78 32.72 335 10306 31484 79702263
Balance disorder 978.19 32.72 398 10243 98459 79635288
Depressed level of consciousness 870.58 32.72 364 10277 96288 79637459
Mobility decreased 701.82 32.72 336 10305 121839 79611908
Fall 680.77 32.72 541 10100 487088 79246659
Constipation 595.21 32.72 403 10238 282647 79451100
Hypotension 493.25 32.72 431 10210 439886 79293861
Toxicity to various agents 370.81 32.72 361 10280 421179 79312568
Pain 190.32 32.72 337 10304 703465 79030282
Multiple drug therapy 86.88 32.72 29 10612 4049 79729698
Drug ineffective 79.71 32.72 23 10618 1080890 78652857
Marasmus 46.31 32.72 13 10628 1015 79732732
Pleurothotonus 42.34 32.72 15 10626 2501 79731246
Fatigue 41.45 32.72 38 10603 929689 78804058
Arthralgia 40.48 32.72 13 10628 571790 79161957
Headache 36.54 32.72 21 10620 653751 79079996
Bradycardia 33.80 32.72 63 10578 135494 79598253

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06DA04 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
FDA MoA N0000000177 Cholinesterase Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D002800 Cholinesterase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018697 Nootropic Agents
MeSH PA D010277 Parasympathomimetics
MeSH PA D018373 Peripheral Nervous System Agents
FDA EPC N0000175723 Cholinesterase Inhibitor
CHEBI has role CHEBI:37733 EC 3.1.1.8 inhibitor
CHEBI has role CHEBI:38323 cholinergic drugs
CHEBI has role CHEBI:38462 acetylcholinesterase inhibitors
CHEBI has role CHEBI:74530 curare poisoning antidote
CHEBI has role CHEBI:76924 plant metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Alzheimer's disease indication 26929004 DOID:10652
Diffuse Lewy body disease off-label use 80098002
Moderate to Severe Alzheimer's Type Dementia off-label use
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Gastrointestinal ulcer contraindication 40845000
Bradycardia contraindication 48867003
Duodenal ulcer disease contraindication 51868009 DOID:1724
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Asthma contraindication 195967001 DOID:2841
Atrioventricular block contraindication 233917008 DOID:0050820
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Acetylcholinesterase Enzyme INHIBITOR Ki 7.21 CHEMBL CHEMBL
Cholinesterase Enzyme Ki 6.72 CHEMBL
Acetylcholinesterase Enzyme IC50 6.44 CHEMBL
Acetylcholinesterase Enzyme IC50 5.60 CHEMBL
Butyrylcholinesterase; Protein Bche Enzyme IC50 5.23 CHEMBL
Acetylcholinesterase Enzyme IC50 6.27 CHEMBL
Acetylcholinesterase Enzyme Ki 6.37 CHEMBL
Acetylcholinesterase Enzyme IC50 5.06 CHEMBL
Butyrylcholinesterase Enzyme Ki 5.10 CHEMBL
Cholinesterase Enzyme Ki 5.03 CHEMBL

External reference:

IDSource
4021250 VUID
N0000148691 NUI
D02173 KEGG_DRUG
1953-04-4 SECONDARY_CAS_RN
4021250 VANDF
4021251 VANDF
C0016967 UMLSCUI
CHEBI:42944 CHEBI
GNT PDB_CHEM_ID
CHEMBL659 ChEMBL_ID
DB00674 DRUGBANK_ID
CHEMBL1555 ChEMBL_ID
D005702 MESH_DESCRIPTOR_UI
9651 PUBCHEM_CID
6693 IUPHAR_LIGAND_ID
1392 INN_ID
0D3Q044KCA UNII
4637 RXNORM
147848 MMSL
15913 MMSL
d04750 MMSL
007026 NDDF
007027 NDDF
129482002 SNOMEDCT_US
323377002 SNOMEDCT_US
395727007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Galantamine Hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 0054-0137 SOLUTION 4 mg ORAL ANDA 25 sections
Galantamine Hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 0054-0137 SOLUTION 4 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3496 CAPSULE, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3496 CAPSULE, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3497 CAPSULE, EXTENDED RELEASE 16 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3497 CAPSULE, EXTENDED RELEASE 16 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3498 CAPSULE, EXTENDED RELEASE 24 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3498 CAPSULE, EXTENDED RELEASE 24 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7104 TABLET, FILM COATED 4 mg ORAL ANDA 26 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0881 TABLET, FILM COATED 4 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0881 TABLET, FILM COATED 4 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0882 TABLET, FILM COATED 8 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0882 TABLET, FILM COATED 8 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0883 TABLET, FILM COATED 12 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0883 TABLET, FILM COATED 12 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0891 CAPSULE, EXTENDED RELEASE 8 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0891 CAPSULE, EXTENDED RELEASE 8 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0892 CAPSULE, EXTENDED RELEASE 16 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0892 CAPSULE, EXTENDED RELEASE 16 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0893 CAPSULE, EXTENDED RELEASE 24 mg ORAL NDA 28 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0893 CAPSULE, EXTENDED RELEASE 24 mg ORAL NDA 28 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 21695-184 TABLET, FILM COATED 8 mg ORAL NDA 20 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 21695-591 TABLET, FILM COATED 12 mg ORAL NDA 20 sections
Galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 43353-984 CAPSULE, EXTENDED RELEASE 16 mg ORAL ANDA 20 sections
Galantamine Hydrobromide Human Prescription Drug Label 1 47335-835 CAPSULE, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Galantamine Hydrobromide Human Prescription Drug Label 1 47335-835 CAPSULE, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Galantamine Hydrobromide Human Prescription Drug Label 1 47335-836 CAPSULE, EXTENDED RELEASE 16 mg ORAL ANDA 25 sections
Galantamine Hydrobromide Human Prescription Drug Label 1 47335-836 CAPSULE, EXTENDED RELEASE 16 mg ORAL ANDA 25 sections
Galantamine Hydrobromide Human Prescription Drug Label 1 47335-837 CAPSULE, EXTENDED RELEASE 24 mg ORAL ANDA 25 sections
Galantamine Hydrobromide Human Prescription Drug Label 1 47335-837 CAPSULE, EXTENDED RELEASE 24 mg ORAL ANDA 25 sections